Recent clinical trials conducted in Kwale County, Kenya, and Mozambique have demonstrated that the repurposed drug ivermectin can reduce malaria transmission by 26%. The cluster-randomized trial compared ivermectin to albendazole, a control drug, and found a significant reduction in malaria infection incidence among children who received ivermectin. Experts suggest that this prophylactic use of ivermectin could decrease the overall use of antimicrobials, potentially lowering the risk of antimicrobial resistance. While ivermectin has shown benefits in reducing malaria transmission, data indicates that mortality benefits are predominantly observed in individuals aged 60 and older, with children and adolescents accounting for a minimal proportion of lives saved. The findings have been published and discussed in the New England Journal of Medicine, highlighting ivermectin as a promising tool in malaria control efforts.